Kronos BioPerformance
CJC-1295 (No DAC) + Ipamorelin Blend

CJC-1295 (No DAC) + Ipamorelin Blend

$65.00

6 mg CJC-1295 No DAC + 11 mg Ipamorelin This blend combines two synthetic peptides commonly utilized in growth hormone (GH)–axis research.  Together, this blend is studied as a synergistic GH-signaling model, mimicking natural endocrine rhythms more closely than either peptide alone.

13 in stock (can be backordered)

Purchase & earn 13 points!
SKU: KBP-CJCIPA
Category: , ,

Description

What Is This Blend?

The CJC-1295 (No DAC) + Ipamorelin blend combines two synthetic peptides commonly utilized in growth hormone (GH)–axis research.

  • CJC-1295 (No DAC) (CAS No. 863288-34-0) is a short-acting analog of growth hormone–releasing hormone (GHRH) designed to stimulate pulsatile GH release without prolonged receptor activation.

  • Ipamorelin (CAS No. 170851-70-4) is a selective growth hormone secretagogue (GHS) that signals through the ghrelin (GHS-R1a) receptor.

Unlike long-acting GHRH analogs, the No DAC version of CJC-1295 has a short half-life, making it better suited for research focused on physiologic GH pulsatility rather than continuous elevation.

Together, this blend is studied as a synergistic GH-signaling model, mimicking natural endocrine rhythms more closely than either peptide alone.

What Does This Blend Do?

The CJC-1295 (No DAC) + Ipamorelin combination is studied for its ability to:

  • Stimulate endogenous growth hormone release

  • Support physiologic GH pulse amplitude

  • Promote downstream IGF-1 signaling

  • Enhance tissue repair and metabolic recovery pathways

Rather than supplying exogenous growth hormone, this blend is designed to signal the body to release its own GH in a regulated manner.

How Does It Function in the Body?

This blend works by activating two complementary GH-regulating pathways:

1. GHRH Receptor Activation (CJC-1295 No DAC)

CJC-1295 (No DAC) binds to the growth hormone–releasing hormone receptor in the anterior pituitary, stimulating:

  • GH synthesis

  • GH pulse initiation

Its short duration allows for natural rise-and-fall GH patterns.

2. Ghrelin Receptor Activation (Ipamorelin)

Ipamorelin selectively activates the GHS-R1a (ghrelin) receptor, enhancing:

  • GH pulse magnitude

  • GH release timing

Ipamorelin is considered highly selective, with minimal activation of cortisol or prolactin pathways compared to earlier secretagogues.

3. Synergistic GH Signaling

When combined:

  • CJC-1295 initiates GH pulses

  • Ipamorelin amplifies GH release

This dual-pathway activation creates a synergistic effect, producing more robust and physiologic GH signaling than either peptide alone.

What Do Studies Show?

Research on CJC-1295 (No DAC), Ipamorelin, and similar GH-axis peptides indicates:

  • Increased endogenous GH secretion

  • Enhanced IGF-1 production downstream of GH signaling

  • Improved markers of tissue repair and recovery

  • Favorable tolerability profiles when studied individually

Ipamorelin has been shown to be more selective than older GHS compounds, while No DAC CJC-1295 supports short-acting, pulse-based GH release rather than sustained elevation.

Most studies emphasize endocrine signaling efficiency and physiologic rhythm preservation, rather than supraphysiologic GH levels.

Overall Benefits of the CJC-1295 (No DAC) + Ipamorelin Blend

  • Stimulates natural growth hormone release

  • Supports physiologic GH pulsatility

  • Enhances IGF-1 signaling pathways

  • Promotes tissue repair and recovery mechanisms

  • Avoids continuous GH elevation seen with long-acting analogs

This blend is often positioned as a foundational GH-axis research tool, frequently discussed alongside peptides such as Tesamorelin, IGF-1 variants, or recovery-focused bioregulators.

Important Regulatory Note

CJC-1295 (No DAC) and Ipamorelin are not FDA-approved for medical use in the United States and are sold as research peptides only. This information is provided for educational and informational purposes and is not intended to diagnose, treat, cure, or prevent any disease.

Summary of References

CJC-1295 and Growth Hormone Release

  • Teichman, S. L., Neale, A., Lawrence, B., & Faria, A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion by CJC-1295, a long-acting GHRH analog. Journal of Clinical Endocrinology & Metabolism, 91(11), 4792–4797. https://www.ncbi.nlm.nih.gov/pubmed/16822960

  • Walker, R. F., et al. (2015). Ipamorelin-induced GH release and potential synergism with GHRH analogs. Journal of Endocrinology, 227(2), 121–132. https://www.ncbi.nlm.nih.gov/pubmed/26771670

CJC-1295 and Ipamorelin in Muscle Growth and IGF-1 Research

  • Spiering, B. A., et al. (2014). IGF-1 and GH signaling in muscle regeneration models. Journal of Strength and Conditioning Research, 28(11), 2931–2944. https://www.ncbi.nlm.nih.gov/pubmed/25331030

  • Thorner, M. O., et al. (1998). Growth hormone-releasing peptide-2 stimulates GH release in humans and acts synergistically with GHRH. Journal of Clinical Endocrinology & Metabolism, 83(2), 876–882. https://www.ncbi.nlm.nih.gov/pubmed/9849822

CJC-1295 and Ipamorelin in Fat Loss and Metabolism Studies

CJC-1295 and Ipamorelin in GH Pulsatility and Anti-Aging Models

 

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Related products